Export

Doxorubicin
Essential medicine status
General description
Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.
INN
Doxorubicin
ATC codes
L01DB01 L01AA01
Medicine type
Chemical agent
EML status history
Added in 2015 (TRS 994) for Follicular lymphoma
Added in 2015 (TRS 994) for Hodgkin lymphoma
Added in 2019 (TRS 1021) for Plasma cell myeloma
Application rejected in 2021 (TRS 1035) for Rhabdomyosarcoma primary site
Wikipedia
Doxorubicin
DrugBank
Doxorubicin
Recommendations
Section
Cytotoxic medicines
  • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
  • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
  • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)
Indications
Diffuse large B-cell lymphomas Malignant neoplasms of breast Hodgkin lymphoma Kaposi sarcoma of unspecified primary site Follicular lymphoma Unspecified malignant neoplasms of ill-defined or unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia Other specified malignant neoplasms of breast Plasma cell myeloma Rhabdomyosarcoma primary site Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative